Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: Lessons from the FRALLE 93 protocol

Haematologica

Volumn 97, Issue 11, 2012, Pages 1743-1750

  Gandemer, Virginie ^a   Chevret, Sylvie ^b   Petit, Arnaud ^c   Vermylen, Christiane ^d   Leblanc, Thierry ^e   Michel, Gérard ^f   Schmitt, Claudine ^g   Lejars, Odile ^h   Schneider, Pascale ⁱ   Demeocq, François ^j   Bader Meunier, Brigitte ^k   Bernaudin, Françoise ^l   Perel, Yves ^m   Auclerc, Marie Françoise ^b   Cayuela, Jean Michel ⁿ   Leverger, Guy ^c   Baruchel, André ^e  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d Department of Pediatric Hematology of Brussels ^*  (Belgium)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f University Hospital of Marseille   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^k BICÊTRE HOSPITAL   (France)

^l Department of Pediatric Hematology   (France)

^m BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁿ SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Acute lymphoblastic; Childhood leukemia; ETV6 RUNX1; Prognosis; Relapse

Indexed keywords

ASPARAGINASE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MITOXANTRONE; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORTISONE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; VINCRISTINE;

EID: 84868544636     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.059584     Document Type: Article

References (39)

1. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010;24(2):309-19.
2. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2): 265-84.
3. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24 (2):371-82.
4. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia. 2010;24 (2):355-70.
5. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, et al. Longterm results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24(2):320-34.
6. Chessells JM, Veys P, Kempski H, Henley P, Leiper A, Webb D, et al. Long-term followup of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123 (3):396-405.
7. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study[corrected]. J Clin Oncol. 2008;26(24):3971-8.
8. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia-lessons from the United Kingdom R2 trial. Br J Haematol. 2005;130 (1):67-75.
9. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339-47.
10. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579-87.
11. Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood. 2003;101(10):3835-9.
12. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group experience. Cancer. 1998;82(7):1387-95.
13. Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006;107(11):4508-13.
14. Burmeister T, Gokbuget N, Schwartz S, Fischer L, Hubert D, Sindram A, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica. 2009;95(2):241-6.
15. Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgstrom G, et al. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol. 2008;140(6):665-72.
16. Ford AM, Fasching K, Panzer-Grumayer ER, Koenig M, Haas OA, Greaves MF. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood. 2001;98(3):558-64.
17. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, et al. Initiating and cancerpropagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319 (5861):336-9.
18. Pine SR, Wiemels JL, Jayabose S, Sandoval C. TEL-AML1 fusion precedes differentiation to pre-B cells in childhood acute lymphoblastic leukemia. Leuk Res. 2003;27(2): 155-64.
19. Zuna J, Ford AM, Peham M, Patel N, Saha V, Eckert C, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2004;10(16):5355-60.
20. Chow CD, Dalla-Pozza L, Gottlieb DJ, Hertzberg MS. Two cases of very late relapsing ALL carrying the TEL:AML1 fusion gene. Leukemia. 1999;13(11):1893-4.
21. Ly-Sunnaram B, Henry C, Gandemer V, Mee FL, Burtin F, Blayau M, et al. Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis. Leuk Res. 2005;29(9):1089-94.
22. Dufourg MN, Landman-Parker J, Auclerc MF, Schmitt C, Perel Y, Michel G, et al. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia. 2007;21(2):238-47.
23. Domenech C, Mercier M, Plouvier E, Puraveau M, Bordigoni P, Michel G, et al. First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study. Eur J Cancer. 2008;44 (16):2461-9.
24. Capizzi RL, Poole M, Cooper MR, Richards F 2nd, Stuart JJ, Jackson DV Jr, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood. 1984;63(3):694-700.
25. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27(3):377-84.
26. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90(12):4933-7.
27. Seeger K, Buchwald D, Taube T, Peter A, von Stackelberg A, Schmitt G, et al. TELAML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt-Munster Study Group. Leukemia. 1999;13(9):1469-70.
28. Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for Lasparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96(3): 1094-9.
29. Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia. 2012;26(2)265-70.
30. Hagedorn N, Acquaviva C, Fronkova E, von Stackelberg A, Barth A, zur Stadt U, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood. 2007;110(12):4022-9.
31. Konrad M, Metzler M, Panzer S, Ostreicher I, Peham M, Repp R, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood. 2003;101(9):3635-40.
32. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA. 1998;95(8):4584-8.
33. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354(9189):1499-503.
34. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377-80.
35. Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006;108(2): 711-7.
36. Staal FJ, de Ridder D, Szczepanski T, Schonewille T, van der Linden EC, van Wering ER, et al. Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia. 2010;24(3):491-9.
37. Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood. 2011;117(9):2658-67.
38. Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011;117(11):3010-5.
39. Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358(9289):1239-41.